Osteoarthritis (OA) is increasingly prevalent as the population ages, and current treatments focus on the relatively short-term relief of symptoms. Clinical trials of disease modifi cation are expensive, requiring prolonged followup of large numbers of participants. In the current global fi nancial climate, there is renewed interest in the OAmodifying potential of existing treatments that have been developed for other indications. Bisphosphonates represent one such class of agent, and the paper by Moreau and colleagues [1] in a recent issue of Arthritis Research & Th erapy provided useful insights into the potential of this class for OA.
hetero genous disease that varies with time, inadequate targeting to those most likely to benefi t. Collectively, these reports raise some important questions about the use of bisphosphonates and general issues for the development of new treatments in OA. How clinically relevant are animal models? Which key pathogenic mechanisms are amenable to intervention? How can treatments be targeted to those mechanisms in the right people at the right time?
Surgical models build on the well-recognized asso ciation between OA and preceding internal derangement [3] . Th eir predictable onset and rapid development by comparison with spontaneous models facilitate the testing of pharmacological interventions. Most researchers use small-rodent models of OA, although it has been argued that these may inadequately represent the pathogenic processes in humans because of diff erences in aging and joint biomechanics. Moreau and colleagues partially avoided these problems by studying OA in dogs, although this raises its own ethical issues. Th e authors maximized the scientifi c outputs from their study by reporting multiple clinical, biochemical, and histological outcomes. Th ey minimized animal numbers by referring to historical controls rather than using sham surgery. Th is does, however, hinder interpretation of whether anti-infl ammatory eff ects are directed at OA itself or post-surgical infl ammation.
Bisphosphonates could act through several mechanisms. Abnormal bone turnover in OA leads to a zone of osteoporosis beneath the thickened subchondral plate, altered fl exibility, and increased microfracture [4] . Osteoclasts mediate the extension of channels from marrow spaces into the non-calcifi ed articular cartilage. Th e resulting loss of osteochondral integrity exposes subchondral nerves to proinfl ammatory and algesic factors from the synovial fl uid and permits sensory nerve growth into the non-calcifi ed articular cartilage [5] . Furthermore, osteoclasts may reduce pH at the osteochondral junction, thereby sensitizing and activating sensory nerves through actions on ion channels on their peripheral terminals [6] .
Th e data of Moreau and colleagues are consistent with eff ects of bisphosphonates on subchondral bone turnover but also suggest possible actions on synovitis. Infl am mation is a common feature of OA and is associated both with symptoms and with structural progression [7] . Infl am mation in OA synovium is characterized by a predominance of macrophages, which can be targeted by bisphosphonates [8] . However, anti-infl ammatory cyclooxygenase inhibitors and glucocorticosteroids have only short-term eff ects on pain in humans. Th is may be because the catabolic eff ects of these inhibitors and gluco corticosteroids off set potential long-term clinical benefi t, and the possibility that bisphosphonates may protect joint structure while inhibiting infl ammation deserves further study.
Th e quest for structural disease modifi cation in OA has focused largely on joint space narrowing, indicative of cartilage loss and meniscal extrusion, and osteophytosis. However, each of these defi nes structures that may not be direct sources of pain. Th e data of Moreau and colleagues support the fi ndings of other groups indicating that structural treatments, despite having little eff ect on chondropathy or osteophytosis, could reduce pain [9] . Magnetic resonance imaging features more closely associated with pain in OA include synovitis and bone marrow lesions.
Bone marrow lesions identify regions of increased subchondral bone turnover and therefore may provide a biomarker that can predict response to bisphosphonates. Laslett and colleagues [10] recently reported a placebocontrolled trial of the potent parenteral bisphosphonate, zoledronic acid, and showed improved pain in people with OA and bone marrow lesions. It remains to be determined, however, whether bisphosphonates act exclusively through subchondral bone turnover or whether they may also be eff ective if targeted to people during OA-associated synovitis.
Animal models refl ect the understanding of the pathogenesis of OA at the time they were developed. Investigating subchondral bone changes and synovitis requires a critical use and refi nement of these models. A better understanding of how they refl ect the clinical spectrum of OA will facilitate the translation of novel treatments to clinical practice. Th e bisphosphonate story continues to evolve and there remains optimism that it may lead to targeted treatments with greater eff ectiveness in the near future.
Abbreviation OA, osteoarthritis.
